Sodium Bicarbonate Supplementation in Athletes

May 23, 2017 updated by: Poznan University of Life Sciences

The Effect of Sodium Bicarbonate Supplementation on Physical Capacity and Body Composition in Trained Athletes

The purpose of this study was to verify the effect of 10-day sodium bicarbonate (NaHCO3) and placebo (PLA) supplementation on body composition, physical capacity, as well as concentrations of the selected biochemical blood markers in trained athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Study Overview

Detailed Description

Sodium bicarbonate (NaHCO3) was proposed as an ergogenic agent, because it improves high-intensity and resistance exercise performance. Until now the major limitation to NaHCO3 supplementation has been the gastrointestinal (GI) side effects. Therefore, this study aims to examine the effect of chronic, progressive- dose NaHCO3 ingestion on physical capacity, body composition and concentrations of the selected biochemical blood markers in trained athletes, in a randomised, double-blind, placebo-controlled crossover trial.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wielkopolska
      • Poznań, Wielkopolska, Poland, 60-624
        • Poznan University of Life Sciences, ul.Wojska Polskiego 31

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 41 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • written consent to participate,
  • a current medical clearance to practice sports,
  • training experience: at least 2 years (of CrossFit training),
  • minimum of 3 workout sessions (CrossFit) a week,
  • 20-43 years.

Exclusion Criteria:

  • current injury,
  • any health-related contraindication,
  • declared general feeling of being unwell,
  • unwilling to follow the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sodium bicarbonate

Group taking oral NaHCO3 supplementation in a progressive-dose regimen.

Interventions:

The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.

Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced.

Placebo Comparator: Placebo (maltodextrin)

Group taking oral supplementation with placebo (maltodextrin).

Interventions:

The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.

Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in aerobic capacity after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
The incremental cycling test (ICT)
Baseline and after 10 days
Changes in specific performance capacity after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
The CrossFit-specific physical fitness test: Fight Gone Bad (FGB)
Baseline and after 10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in fat mass and fat free mass after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
Fat mass (kg) and fat free mass (kg) analysis
Baseline and after 10 days
Changes of red and white blood cell concentration in blood after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
Red blood cells (RBC) [mln/mm³] and white blood cells (WBC) [mln/mm³] concentration analysis
Baseline and after 10 days
Changes in blood glucose and hemoglobin concentration after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
Hemoglobin (Hb) [g/dl] and glucose [g/dl] concentration analysis
Baseline and after 10 days
Changes in blood hematocrit levels after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
Hematocrit (HCT) [%] level analysis
Baseline and after 10 days
Changes of lactate and pyruvate concentration in blood after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
Lactate [mmol/L] and pyruvate [mmol/L] concentration analysis
Baseline and after 10 days
Changes of creatine kinase and lactate dehydrogenase activity in blood after sodium bicarbonate supplementation
Time Frame: Baseline and after 10 days
Creatine kinase [U/L] and lactate dehydrogenase [U/L] activity analysis
Baseline and after 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Jan Jeszka, Professor, Department of Hygiene and Human Nutrition, Poznan University of Life Sciences, Poznan, Poland

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2015

Primary Completion (Actual)

March 10, 2016

Study Completion (Actual)

April 5, 2016

Study Registration Dates

First Submitted

May 22, 2017

First Submitted That Met QC Criteria

May 23, 2017

First Posted (Actual)

May 24, 2017

Study Record Updates

Last Update Posted (Actual)

May 24, 2017

Last Update Submitted That Met QC Criteria

May 23, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • ULS00002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Shared data will be exclusively related to the level recorded indicators (body composition, aerobic and anaerobic capacity indicators, levels of biochemical markers), without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Supplementation

Clinical Trials on Sodium bicarbonate supplementation

3
Subscribe